Search Results

You are looking at 1 - 10 of 13 items for :

  • thyroid cancer x
Clear All
Open access

Vineeth Sukrithan, Prachi Jain, Manisha H Shah, and Bhavana Konda

Introduction Differentiated thyroid cancers (DTCs) represent the most common type of thyroid cancers (85%), followed by medullary thyroid cancers (MTCs) and anaplastic thyroid cancers (ATCs), representing 2 to 8% and 1%, respectively ( Porter

Open access

T U Kars, M Kulaksızoğlu, and İ Kılınç

Introduction Thyroid cancer is the most common cancer of the endocrine system, with a continuously increasing incidence in the last decades ( Pellegriti et al. 2013 ). Papillary thyroid carcinoma is the most prevalent histologic type

Open access

Patrick W Owens, Terri Patricia McVeigh, Nicola Miller, Carole Guerin, Frederic Sebag, Denis Quill, Marcia Bell, Michael J Kerin, and Aoife J Lowery

Introduction Thyroid cancer is the most common endocrine malignancy with an increasing incidence recorded over recent decades in Western countries, including Ireland. Genetic factors play a significant role in the determination of thyroid

Open access

Benjamin J Worrall, Alexander Papachristos, Ahmad Aniss, Anthony Glover, Stan B Sidhu, Roderick J Clifton-Bligh, Diana Learoyd, Venessa H M Tsang, Matti Gild, Bruce G Robinson, and Mark S Sywak

Introduction Papillary thyroid carcinoma (PTC) is the most common subtype of differentiated thyroid cancer, which comprises over 90% of all thyroid cancers ( Sherman 2003 , Haugen 2016 ). PTC has the best prognosis of all thyroid cancer

Open access

Krishna Vikneson, Tariq Haniff, May Thwin, Ahmad Aniss, Alex Papachristos, Mark Sywak, and Anthony Glover

Introduction Well-differentiated thyroid cancer (DTC) and papillary thyroid cancer (PTC) incidence has been increasing in comparison to other thyroid cancers ( Davies & Welch 2014 , Davies & Hoang 2021 ). However, most thyroid cancer

Open access

Alexander Kreze, Matěj Homer, Tereza Barešová, and Kristina Klemperová

monoclonal antibodies directed against these regulatory checkpoint molecules (immune checkpoint inhibitors (ICIs)) are used to treat some types of cancer. PD-1 is an immune inhibitory receptor expressed on activated T cells, B cells, macrophages and natural

Open access

Macarena Contreras Angulo, Belén García Izquierdo, Laura Armengod Grao, and Nuria Palacios García

, Nakashima et al. 2022 ). Although advanced neoplasm could be a potential cause of systemic TMA in our case, we consider it unlikely as no cases have been described associated with thyroid cancer in the absence of other recognized etiologic factors

Open access

D Mc Donald, M Sherlock, and C J Thompson

important aspect of oncological treatment, there is a growing awareness of the detrimental effects of hyponatraemia in cancer patients. Numerous studies have demonstrated that hyponatraemia confers poorer prognosis in patients with malignancy, and as

Open access

Sandra Pekic, Marko Stojanovic, and Vera Popovic

et al. 2014 , Terzolo et al. 2017 , Esposito et al. 2018 , 2021 ). Large epidemiological and observational studies on all cancers, colorectal cancer and thyroid cancers show inconsistent results ( Orme et al. 1998 , Jenkins & Besser 2001

Open access

Yixi Bi, Safwaan Adam, Viktoria Chatzimavridou, Paul Lorigan, and Yinglai Huang

Background Immune checkpoint inhibitors (ICI) have revolutionised the management of malignancies, including melanoma, non-small cell lung cancer and renal cell carcinoma. Secondary adrenal insufficiency in the context of ICI use has been